4//SEC Filing
Dhingra Ankur 4
Accession 0001599298-22-000102
CIK 0001599298other
Filed
Aug 16, 8:00 PM ET
Accepted
Aug 17, 4:49 PM ET
Size
6.8 KB
Accession
0001599298-22-000102
Insider Transaction Report
Form 4
Dhingra Ankur
Chief Financial Officer
Transactions
- Purchase
Common Stock
2022-08-16$0.97/sh+11,557$11,210→ 38,057 total - Purchase
Common Stock
2022-08-16$0.97/sh+24,658$23,918→ 38,196 total(indirect: By Trust)
Footnotes (2)
- [F1]Represents the number of shares of Common Stock that the Reporting Person purchased in the Issuer's rights offering.
- [F2]The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Documents
Issuer
Summit Therapeutics Inc.
CIK 0001599298
Entity typeother
Related Parties
1- filerCIK 0001849682
Filing Metadata
- Form type
- 4
- Filed
- Aug 16, 8:00 PM ET
- Accepted
- Aug 17, 4:49 PM ET
- Size
- 6.8 KB